Streetbeat News

Price Targets

CCK

UBS analyst Cleveland Rueckert has initiated coverage on Crown Holdings (NYSE:CCK) with a Buy rating and set a price target of $112.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 4:09 pm

FND

Floor & Decor Holdings (NYSE:FND) has received mixed analyst ratings over the last three months, with a total of 12 analysts offering diverse outlooks. The recent ratings show a shift towards a more cautious stance, with fewer bullish and more indifferent ratings in the last 30 days. Analysts have adjusted their 12-month price targets for FND, resulting in an average target of $91.75, a decrease from the previous average. The company has shown positive revenue growth and a strong net margin but has a below-average ROE. Its market capitalization is below industry averages, and it maintains a moderate debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 16, 2024 | 4:00 pm

BALL

UBS analyst Cleveland Rueckert has initiated coverage on Ball Corporation (NYSE:BALL) with a Sell rating and set a price target of $55. This new coverage could influence investor sentiment and potentially impact Ball's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:59 pm

AMBP

UBS analyst Curt Woodworth has initiated coverage on Ardagh Metal Packaging (NYSE:AMBP) with a Buy rating and set a price target of $5.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:58 pm

WDC

Western Digital's stock (WDC) is trading higher following an upgrade from Deutsche Bank, which changed its rating from Hold to Buy and increased the price target from $45 to $65.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:55 pm

AA

UBS analyst Curt Woodworth has initiated coverage on Alcoa (NYSE:AA) with a Sell rating and set a price target of $29. This new coverage could influence investor sentiment and potentially impact Alcoa's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:53 pm

LBPH

Cantor Fitzgerald analyst Josh Schimmer has maintained an Overweight rating on Longboard Pharmaceuticals (LBPH) and increased the price target from $55 to $60.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:43 pm

MCRB

Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Seres Therapeutics (NASDAQ:MCRB) but has reduced the price target from $10 to $9. This adjustment reflects a revised valuation of the company's prospects.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:37 pm

RXST

Oppenheimer analyst Steven Lichtman has maintained an Outperform rating on RxSight (NASDAQ:RXST) and increased the price target from $46 to $50, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:33 pm

JPM

Oppenheimer analyst Chris Kotowski has maintained an Outperform rating on JPMorgan Chase (NYSE:JPM) but has reduced the price target from $234 to $232.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 3:30 pm